UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 43.

Wick, W; Roth, P; Hartmann, C; Hau, P; Nakamura, M; Stockhammer, F; Sabel, M C; Wick, A; Koeppen, S; Ketter, R; Vajkoczy, P; Eyupoglu, I; Kalff, R; Pietsch, T; Happold, C; Galldiks, N; Schmidt-Graf, F; Bamberg, M; Reifenberger, G; Platten, M; von Deimling, A; Meisner, C; Wiestler, B; Weller, M (2016). Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 18(11):1529-1537.

Mangani, D; Weller, M; Seyed Sadr, E; Willscher, E; Seystahl, K; Reifenberger, G; Tabatabai, G; Binder, H; Schneider, H (2016). Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models. Neuro-Oncology, 18(12):1610-1621.

Suchorska, B; Weller, M; Tabatabai, G; Senft, C; Hau, P; Sabel, M C; Herrlinger, U; Ketter, R; Schlegel, U; Marosi, C; Reifenberger, G; Wick, W; Tonn, J C; Wirsching, H G (2016). Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-Oncology, 18(4):549-556.

Stojcheva, Nina; Schechtmann, G; Sass, S; Roth, P; Florea, A M; Stefanski, A; Stühler, K; Wolter, M; Müller, N S; Theis, F J; Weller, M; Reifenberger, G; Happold, C (2016). MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. OncoTarget, 7(11):12937-12950.

Codó, P; Weller, M; Kaulich, K; Schraivogel, D; Silginer, M; Reifenberger, G; Meister, G; Roth, P (2016). Control of glioma cell migration and invasiveness by GDF-15. OncoTarget, 7(7):7732-7746.

Gramatzki, Dorothee; Roth, P; Felsberg, J; Hofer, S; Rushing, E J; Hentschel, B; Westphal, M; Krex, D; Simon, M; Schnell, O; Wick, W; Reifenberger, G; Weller, M (2016). Chemotherapy for intracranial ependymoma in adults. BMC Cancer, 16(1):287.

Weller, Michael; Weber, Ruthild G; Willscher, Edith; Riehmer, Vera; Hentschel, Bettina; Kreuz, Markus; Felsberg, Jörg; Beyer, Ulrike; Löffler-Wirth, Henry; Kaulich, Kerstin; Steinbach, Joachim P; Hartmann, Christian; Gramatzki, D; Schramm, J; Westphal, M; Schackert, G; Simon, M; Martens, T; Boström, J; Hagel, C; Sabel, M; Krex, D; Tonn, J C; Wick, W; Noell, S; Schlegel, U; Radlwimmer, B; Pietsch, T; Loeffler, M; von Deimling, A; Binder, H; Reifenberger, G (2015). Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathologica, 129(5):679-693.

Weller, Michael; Tabatabai, G; Kästner, B; Felsberg, J; Steinbach, J P; Wick, A; Schnell, O; Hau, P; Herrlinger, U; Sabel, M C; Wirsching, H G; Ketter, R; Bähr, O; Platten, M; Tonn, J C; Schlegel, U; Marosi, C; Goldbrunner, R; Stupp, R; Homicsko, K; Pichler, J; Nikkhah, G; Meixensberger, J; Vajkoczy, P; Kollias, S; Hüsing, J; Reifenberger, G; Wick, W (2015). MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 21(9):2057-2064.

Wolpert, F; Happold, C; Reifenberger, G; Florea, A M; Deenen, R; Roth, P; Neidert, M C; Lamszus, K; Westphal, M; Weller, M; Eisele, G (2015). Interferon-β modulates the innate immune response against glioblastoma initiating cells. PLoS ONE, 10(10):e0139603.

Ahmad, M; Frei, K; Willscher, E; Stefanski, A; Kaulich, K; Roth, P; Stühler, K; Reifenberger, G; Binder, H; Weller, M (2014). How stemlike are sphere cultures from long-term cancer cell lines? Lessons from mouse glioma models. Journal of Neuropathology and Experimental Neurology, 73(11):1062-1077.

Codo, P; Weller, M; Meister, G; Szabo, E; Steinle, A; Wolter, M; Reifenberger, G; Roth, P (2014). MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. OncoTarget, 5(17):7651-7662.

Weller, M; van den Bent, M; Hopkins, K; Tonn, J C; Stupp, R; Falini, A; Cohen-Jonathan-Moyal, E; Frappaz, D; Henriksson, R; Balana, C; Chinot, O; Ram, Z; Reifenberger, G; Soffietti, R; Wick, W (2014). EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncology, 15(9):e395-e403.

Wiestler, B; Capper, D; Hovestadt, V; Sill, M; Jones, D T W; Hartmann, C; Felsberg, J; Platten, M; Feiden, W; Keyvani, K; Pfister, S M; Wiestler, O D; Meyermann, R; Reifenberger, G; Pietsch, T; von Deimling, A; Weller, M; Wick, W (2014). Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-Oncology, 16(12):1630-1638.

Wiestler, B; Capper, D; Sill, M; Jones, D T W; Hovestadt, V; Sturm, D; Koelsche, C; Bertoni, A; Schweizer, L; Korshunov, A; Weiß, E K; Schliesser, M G; Radbruch, A; Herold-Mende, C; Roth, P; Unterberg, A; Hartmann, C; Pietsch, T; Reifenberger, G; Lichter, P; Radlwimmer, B; Platten, M; Pfister, S M; von Deimling, A; Weller, M; Wick, W (2014). Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 128(4):561-571.

Wick, W; Weller, M; van den Bent, M; Sanson, M; Weiler, M; von Deimling, A; Plass, C; Hegi, M; Platten, M; Reifenberger, G (2014). MGMT testing-the challenges for biomarker-based glioma treatment. Nature Reviews. Neurology, 10(7):372-85.

Weller, M; Kaulich, K; Hentschel, B; Felsberg, J; Gramatzki, D; Pietsch, T; Simon, M; Westphal, M; Schackert, G; Tonn, J C; von Deimling, A; Davis, T; Weiss, W A; Loeffler, M; Reifenberger, G (2014). Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. International Journal of Cancer, 134(10):2437-2447.

Riehmer, V; Gietzelt, J; Beyer, U; Hentschel, B; Westphal, M; Schackert, G; Sabel, M C; Radlwimmer, B; Pietsch, T; Reifenberger, G; Weller, M; Weber, R G; Loeffler, M (2014). Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild-type glioblastoma. Genes, Chromosomes and Cancer, 53(7):589-605.

Happold, C; Roth, P; Silginer, M; Florea, A M; Lamszus, K; Frei, K; Deenen, R; Reifenberger, G; Weller, M (2014). Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. Molecular Cancer Therapeutics, 13(4):948-961.

Reifenberger, G; Weber, R G; Riehmer, V; Kaulich, K; Willscher, E; Wirth, H; Gietzelt, J; Hentschel, B; Westphal, M; Simon, M; Schackert, G; Schramm, J; Matschke, J; Sabel, M C; Gramatzki, D; Felsberg, J; Hartmann, C; Steinbach, J P; Schlegel, U; Wick, W; Radlwimmer, B; Pietsch, T; Tonn, J C; von Deimling, A; Binder, H; Weller, M; Loeffler, M (2014). Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. International Journal of Cancer, 135(8):1822-1831.

Fan, Q W; Cheng, C K; Gustafson, W C; Charron, E; Zipper, P; Wong, R A; Chen, J; Lau, J; Knobbe-Thomsen, C; Weller, M; Jura, N; Reifenberger, G; Shokat, K M; Weiss, W A (2013). EGFR Phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell, 24(4):438-449.

Kreth, F W; Thon, N; Simon, M; Westphal, M; Schackert, G; Nikkhah, G; Hentschel, B; Reifenberger, G; Pietsch, T; Weller, M; Tonn, J C (2013). Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Annals of Oncology, 24(12):3117-3123.

Hartmann, C; Hentschel, B; Simon, M; Westphal, M; Schackert, G; Tonn, J C; Loeffler, M; Reifenberger, G; Pietsch, T; von Deimling, A; Weller, M (2013). Longterm survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clinical Cancer Research, 19(18):5146-5157.

Wiestler, B; Claus, R; Hartlieb, S A; Schliesser, M G; Weiss, E K; Hielscher, T; Platten, M; Dittmann, L M; Meisner, C; Felsberg, J; Happold, C; Simon, M; Nikkhah, G; Papsdorf, K; Steinbach, J P; Sabel, M; Grimm, C; Weichenhan, D; Tews, B; Reifenberger, G; Capper, D; Müller, W; Plass, C; Weller, M; Wick, W (2013). Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro-Oncology, 15(8):1017-1026.

Weller, M; Pfister, S M; Wick, W; Hegi, M E; Reifenberger, G; Stupp, R (2013). Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncology, 14(9):e370-e379.

Wick, W; Meisner, C; Hentschel, B; Platten, M; Schilling, A; Wiestler, B; Sabel, M C; Koeppen, S; Ketter, R; Weiler, M; Tabatabai, G; von Deimling, A; Gramatzki, D; Westphal, M; Schackert, G; Loeffler, M; Simon, M; Reifenberger, G; Weller, M (2013). Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology, 81(17):1515-1522.

Happold, C; Roth, P; Wick, W; Schmidt, N; Florea, A M; Silginer, M; Reifenberger, G; Weller, M (2012). Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. Journal of Neurochemistry, 122(2):444-455.

Weller, M; Stupp, R; Hegi, M E; van den Bent, M; Tonn, J C; Sanson, M; Wick, W; Reifenberger, G (2012). Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-Oncology, 14(Suppl. 4):iv100-iv108.

Reifenberger, G; Hentschel, B; Felsberg, J; Schackert, G; Simon, M; Schnell, O; Westphal, M; Wick, W; Pietsch, T; Loeffler, M; Weller, M (2012). Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. International Journal of Cancer, 131(6):1342-1350.

Wick, W; Platten, M; Meisner, C; Felsberg, J; Tabatabai, G; Simon, M; Nikkhah, G; Papsdorf, K; Steinbach, J P; Sabel, M; Combs, S E; Vesper, J; Braun, C; Meixensberger, J; Ketter, R; Mayer-Steinacker, R; Reifenberger, G; Weller, M (2012). Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology, 13(7):707-715.

Hartmann, C; Hentschel, B; Tatagiba, M; Schramm, J; Schnell, O; Seidel, C; Stein, R; Reifenberger, G; Pietsch, T; von Deimling, A; Loeffler, M; Weller, M (2011). Molecular markers in low-grade gliomas: predictive or prognostic? Clinical Cancer Research, 17(13):4588-4599.

Glas, M; Bähr, O; Felsberg, J; Rasch, K; Wiewrodt, D; Schabet, M; Simon, M; Urbach, H; Steinbach, J P; Rieger, J; Fimmers, R; Bamberg, M; Nägele, T; Reifenberger, G; Weller, M; Herrlinger, U (2011). NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Annals of Neurology, 70(3):445-53.

Felsberg, J; Thon, N; Eigenbrod, S; Hentschel, B; Sabel, M C; Westphal, M; Schackert, G; Kreth, F W; Pietsch, T; Löffler, M; Weller, M; Reifenberger, G; Tonn, J C (2011). Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. International Journal of Cancer, 129(3):659-670.

Kurzwelly, D; Glas, M; Roth, P; Weimann, E; Lohner, H; Waha, A; Schabet, M; Reifenberger, G; Weller, M; Herrlinger, U (2010). Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. Journal of Neuro-Oncology, 97(3):389-392.

Temme, A; Geiger, K D; Wiedemuth, R; Conseur, K; Pietsch, T; Felsberg, J; Reifenberger, G; Tatsuka, M; Hagel, C; Westphal, M; Berger, H; Simon, M; Weller, M; Schackert, G (2010). Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutation. Journal of Neuropathology and Experimental Neurology, 69(6):632-642.

Weller, M; Stupp, R; Reifenberger, G; Brandes, A A; van den Bent, M J; Wick, W; Hegi, M E (2010). MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Reviews. Neurology, 6(1):39-51.

Hartmann, C; Hentschel, B; Wick, W; Capper, D; Felsberg, J; Simon, M; Westphal, M; Schackert, G; Meyermann, R; Pietsch, T; Reifenberger, G; Weller, M; Loeffler, M; von Deimling, A (2010). Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathologica, 120(6):707-718.

Weller, M; Felsberg, J; Hartmann, C; Berger, H; Steinbach, J P; Schramm, J; Westphal, M; Schackert, G; Simon, M; Tonn, J C; Heese, O; Krex, D; Nikkhah, G; Pietsch, T; Wiestler, O; Reifenberger, G; von Deimling, A; Loeffler, M (2009). Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of Clinical Oncology, 27(34):5743-5750.

Wick, W; Hartmann, C; Engel, C; Stoffels, M; Felsberg, J; Stockhammer, F; Sabel, M C; Koeppen, S; Ketter, R; Meyermann, R; Rapp, M; Meisner, C; Kortmann, R D; Pietsch, T; Wiestler, O D; Ernemann, U; Bamberg, M; Reifenberger, G; von Deimling, A; Weller, M (2009). NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide. Journal of Clinical Oncology, 27(32):5874-5880.

Glas, M; Happold, C; Rieger, J; Wiewrodt, D; Bähr, O; Steinbach, J P; Wick, W; Kortmann, R; Reifenberger, G; Weller, M; Herrlinger, U (2009). Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide. Journal of Clinical Oncology, 27(8):1257-1261.

Pfister, S; Remke, M; Benner, A; Mendrzyk, F; Toedt, G; Felsberg, J; Wittmann, A; Devens, F; Gerber, N U; Joos, S; Kulozik, A; Reifenberger, G; Rutkowski, S; Wiestler, O D; Radlwimmer, B; Scheurlen, W; Lichter, P; Korshunov, A (2009). Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. Journal of Clinical Oncology, 27(10):1627-1636.

Hartmann, C; Meyer, J; Balss, J; Capper, D; Mueller, W; Christians, A; Felsberg, J; Wolter, M; Mawrin, C; Wick, W; Weller, M; Herold-Mende, C; Unterberg, A; Jeuken, J W M; Wesseling, P; Reifenberger, G; von Deimling, A (2009). Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica, 118(4):469-474.

Schittenhelm, J; Reifenberger, G; Ritz, R; Nägele, T; Weller, M; Pantazis, G; Capper, D; Beschorner, R; Meyermann, R; Mittelbronn, M (2008). Primary anaplastic ganglioglioma with a small-cell glioblastoma component. Clinical Neuropathology, 27(2):91-95.

Weber, R G; Boström, J; Wolter, M; Baudis, M; Collins, V P; Reifenberger, G; Lichter, P (1997). Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 94(26):14719-14724.

This list was generated on Sun Jul 23 09:58:14 2017 CEST.